检索结果-南通市图书馆

Indian Spices and biotherapeutics in Health and Chronic Disease

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Health 2018年第4期10卷 374-380页

作者： Ian James Martins Centre of Excellence in Alzheimer’s Disease Research and Care Sarich Neuroscience Research Institute Edith Cowan University Nedlands Australia School of Psychiatry and Clinical Neurosciences The University of Western Australia Nedlands Australia McCusker Alzheimer’s Research Foundation Hollywood Medical Centre Nedlands Australia School of Medical and Health Sciences Edith Cowan University Nedlands Australia

The acceleration in the rate of chronic disease that involves insulin resistance has become of concern in various countries. The rate of the most prevalent chronic diseases involves the metabolic syndrome and non alcoholic fatty liver disease (NAFLD) that is closely associated to diabetes and neurodegenerative diseases. biotherapeutics and nutritional biotherapy have become important to reverse these global diseases. biotherapeutics that involves Indian spice therapy requires assessment with relevance to insulin therapy, immunotherapy, antimicrobial therapy and drug therapeutics. Combined insulin therapy and Indian spice therapy regulates human insulin biological activity with relevance to the prevention of uncontrolled intracellular glucose levels and mitochondrial apoptosis. biotherapeutics with nutritional biotherapy that involves the use of various nutrients such as magnesium and phosphatidylinositol (gm/day) is essential to insulin therapy. Factors such as stress, core body temperature and food quality influence biotherapeutics and Indian spice therapy with delayed spice clearance associated with mitochondrial dysfunction (cell apoptosis) and altered drug/caffeine therapy with relevance to the global diabetes pandemic.

关键词： Spices biotherapeutics

Therapeutic applications of genetic code expansion

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Synthetic and Systems Biotechnology 2018年第3期3卷 150-158页

作者： Yujia Huang Tao Liu State Key Laboratory of Natural and Biomimetic Drugs School of Pharmaceutical SciencesPeking UniversityBeijing100191China

In nature,a limited,conservative set of amino acids are utilized to synthesize proteins.Genetic code expansion technique reassigns codons and incorporates noncanonical amino acids(ncAAs)through orthogonal aminoacyltRNA synthetase(aaRS)/tRNA pairs.The past decade has witnessed the rapid growth in diversity and scope for therapeutic applications of this technology.Here,we provided an update on the recent progress using genetic code expansion in the following areas:antibody-drug conjugates(ADCs),bispecific antibodies(BsAb),immunotherapies,long-lasting protein therapeutics,biosynthesized peptides,engineered viruses and cells,as well as other therapeutic related applications,where the technique was used to elucidate the mechanisms of biotherapeutics and drug targets.

关键词： Genetic code expansion Noncanonical amino acids biotherapeutics Antibody-drug conjugates Live-attenuated vaccines

Insights into biological therapeutic strategies for COVID-19

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Fundamental Research 2021年第2期1卷 166-178页

作者： Xiaolong Tian Cheng Li Yanling Wu Tianlei Ying MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology School of Basic Medical SciencesShanghai Medical CollegeFudan UniversityRoom 504Fosun Building131 Dong-an RoadShanghai 200032China

The worldwide pandemic of novel coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)that emerged in late December 2019 requires the urgent development of therapeutic options.So far,numerous studies have investigated and uncovered the underlying epidemiology and clinical characteristics of COVID-19 infections in order to develop effective drugs.Compared with antiviral small-molecule inhibitors,biotherapeutics have unique advantages such as fewer side effects by virtue of their high specificity,and thus can be rapidly developed for promising treatments of COVID-19.Here,we summarize potential biotherapeutics and their mechanisms of action,including convalescent plasma,therapeutic antibodies,peptides,engineered ACE2,interferons,cytokine inhibitors,and RNAi-based therapeutics,and discuss in depth the advancements and precautions for each type of biotherapeutics in the treatment of COVID-19.

关键词： COVID-19 SARS-CoV-2 biotherapeutics Viral entry Viral replication Cytokine storm

Pharmacokinetics and toxicology of therapeutic proteins:Advances and challenges

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Biological Chemistry 2012年第4期3卷 73-92页

作者： Yulia Vugmeyster Frank-Peter Theil Leslie A Khawli Michael W Leach Department of Pharmacokinetics Dynamicsand MetabolismPfizer Inc.AndoverMA 01810United States UCB Pharma Braine l'AleudB-1420 BrusselsBelgium Pharmacokinetic and Pharmacodynamic Sciences Genentech Inc.South San FranciscoCA 94080United States Drug Safety Research and Development Pfizer Inc.AndoverMA 01810United States

Significant progress has been made in understanding pharmacokinetics (PK),pharmacodynamics (PD),as well as toxicity profiles of therapeutic proteins in animals and humans,which have been in commercial development for more than three decades.However,in the PK arena,many fundamental questions remain to be resolved.Investigative and bioanalytical tools need to be established to improve the translation of PK data from animals to humans,and from in vitro assays to in vivo readouts,which would ultimately lead to a higher success rate in drug development.In toxicology,it is known,in general,what studies are needed to safely develop therapeutic proteins,and what studies do not provide relevant information.One of the major complicating factors in nonclinical and clinical programs for therapeutic proteins is the impact of immunogenicity.In this review,we will highlight the emerging science and technology,as well as the challenges around the pharmacokinetic-and safety-related issues in drug development of mAbs and other therapeutic proteins.

关键词： Pharmacokinetics Toxicology Therapeutic proteins biotherapeutics Monoclonal antibodies

biotherapeutics公司和INGENE公司建立联合实验室

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

生物技术通报 1987年第11期 24-24页

作者：刘世珍

由biotherapeutics公司和International Genetic Engineering(INGENE)公司建立的一个新的联合实验室是这两家公司之间早期协定的一个扩大部分。第一个协议要求INGEN-E公司给

关键词：实验室 INGENE 肿瘤抗原 biotherapeutics

Frontier of therapeutic antibody discovery:The challenges and how to face them

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

World Journal of Biological Chemistry 2012年第12期3卷 187-196页

作者： Zhi-Jian Lu Su-Jun Deng Da-Gang Huang Yun He Ming Lei Li Zhou Pei Jin China Novartis Institutes for Biomedical Research Zhangjiang Hi-Tech Park Novartis Institutes for Biomedical Research Inc.250 Massachusetts Avenue

Therapeutic monoclonal antibodies have become an important class of modern medicines.The established technologies for therapeutic antibody discovery such as humanization of mouse antibodies,phage display of human antibody libraries and transgenic animals harboring human IgG genes have been practiced successfully so far,and many incremental improvements are being made constantly.These methodologies are responsible for currently marketed therapeutic antibodies and for the biopharma industry pipeline which are concentrated on only a few dozen targets.A key challenge for wider application of biotherapeutic approaches is the paucity of truly validated targets for biotherapeutic intervention.The efforts to expand the target space include taking the pathway approach to study the disease correlation.Since many new targets are multi-spanning and multimeric membrane proteins there is a need to develop more effective methods to generate antibodies against these difficult targets.The pharmaceutical properties of therapeutic antibodies are an active area for study concentrating on biophysical characteristics such as thermal stability and aggregation propensity.The immunogenicity of biotherapeutics in humans is a very complex issue and there are no truly predictive animal models to rely on.The in silico and T-cell response approaches identify the potential for immunogenicity;however,one needs contingency plans for emergence of antiproduct antibody response for clinical trials.

关键词： Antibody biotherapeutics Biophysical property Bispecific Humanization Immunogenicity Transgenic rodent Phage display Yeast